Home » European Commission Approves Takeda’s Adcetris for Large-Cell Lymphoma
European Commission Approves Takeda’s Adcetris for Large-Cell Lymphoma
The European Commission has approved Takeda’s Adcetris (brentuximab vedotin) as an adjunct treatment for adult patients with previously untreated systemic anaplastic large-cell lymphoma (sALCL).
The approval was based on the results of a phase 3 trial in which Adcetris plus cyclophosphamide, doxorubicin and prednisone demonstrated significant improvement in progression-free survival.
Adcetris is approved in the U.S. for several indications, including sALCL.
Upcoming Events
-
07May
-
14May
-
30May